The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

Many investors seem to have thrown in the towel on the once high-flying pharma stock. But could Pfizer be a no-brainer stock to buy right now, even if its COVID sales continue to plunge?

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales. Let's ...

With the stock trading at a discount now, we delve into the company’s growth drivers and challenges to evaluate if investors should park their cash in Pfizer at this time.

Pfizer stock has fallen over 60% since its peak at $61.71 during the pandemic, driven by its COVID-19 vaccine sales. Pfizer’s revenue finally rose 2.1% YoY in its second quarter of 2024, for the ...

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable ...